EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Future Oncology: Technology, Products, Market and Service Opportunities

  • ID: 296370
  • Newsletter
  • March 2017
  • Region: Global
  • New MEdicine Inc
1 of 3
Future Oncology is an analytical newsletter for executives, researchers, and market analysts in the pharmaceutical, biotechnology, financial, hospital and other health care industries. It provides comprehensive, up-to-date analysis of scientific, technological, clinical and commercial developments in oncology.

Topics Covered in Future Oncology:

Epidemiology
Worldwide (North America, Europe, Japan, etc.) mortality and incidence estimates by gender, cancer subtype and stage; estimates of populations carrying certain markers and under treatment by type of therapy.

Mechanism in Malignancy
Etiology, pathogenesis and markers by type of cancer; exploitation of mechanisms of malignancy (apoptosis, angiogenesis, cell cycle regulation, multi-drug resistance, etc.) in screening, diagnosis, disease monitoring, prognosis and drug development, including databases of agents in development.

Technology Updates
Technological advances such as in vivo and ex vivo gene therapy using a variety of vectors and delivery approaches, monoclonal antibodies in diagnosis and therapy, radiopharmaceuticals, photodynamic therapy, immunotherapy/vaccines, hematopoietic support, and many more.

Drugs in Development, Markets and Developers
Profile of major oncology drug classes (taxanes, topoisomerase I inhibitors, platinum-based drugs, cell cycle regulators, etc.), estimated worldwide markets for commercialized drugs, descriptions of oncology-related operations of various commercial entities, including their affiliations.

Conference Coverage
Coverage of meetings in the cancer and related fields such as the International Congress on Anti-Cancer Chemotherapy (ICACC); International Conference on Monoclonal Antibody Immunoconjugates for Cancer; Annual Meeting of the American Association for Cancer Research (AACR); Digestive Disease Week; Annual Session of the American Society of Clinical Oncology (ASCO); Annual Meeting of the Society of Nuclear Medicine; International Congress of Chemotherapy; Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); and many more.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Example of topics covered in this publication include:

THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFr) PATHWAY IN CANCER

PART II - TARGET CANCER INDICATIONS AND TARGETING APPROACHES
ErbB RECEPTORS ASSOCIATION BY CANCER INDICATION

EPIDERMAL GROWTH FACTOR RECEPTOR (EGFr)
-Colorectal Cancer
-Head and Neck Cancer
-Lung Cancer
-Prostate Cancer
-Ovarian Cancer
-Brain Cancer
-Breast Cancer
-Pancreatic Cancer

HEr2/neu (HEr2, ErbB2)
-Breast Cancer
-Ovarian Cancer
-Pancreatic Cancer
-Osteosarcoma
-Lung Cancer
-Other Malignancies
-HEr3 (ErbB3)
-HEr4 (ErbB4)
-EGFr VARIANT III (EGFrvIII

TARGETING ErbB RECEPTORS FOR THE TREATMENT OF CANCER
-INTRACELLULAR TARGETING
-Reversible and Irreversible Inhibitors
-Specific, Dual, and Pan-ErbB Inhibitors
-EXTRACELLULAR TARGETING
-Naked Monoclonal Antibodies (MAb)
-Bispecific MAb
-Immunoconjugates
-IMMUNOTHERAPIES/VACCINES USING ErbB AS ANTIGENS

MECHANISMS OF RESISTANCE AND TOXICITY
-RESISTANCE
-TOXICITY

MEETING COVERAGE

NEW TARGETS AND DELIVERY SYSTEMS

IN CANCER DIAGNOSIS AND TREATMENT

FROM THE MARCH 2007 CONFERENCE ORGANIZED

BY THE SIDNEY KIMMEL CANCER CENTER IN SAN DIEGO, CA

ADOPTIVE IMMUNOTHERAPY (AI)
-Adoptive Transfer of IL-2-activated Natural Killer (NK) Cells

NOVEL DRUG DELIVERY FOR TUMOR TARGETING AND IMAGING
-Biologic Agents as Delivery Vehicles
-Cytokine-induced killer (CIK) Cells
-Nanotechnology

INTEGRATING MOLECULAR TARGETS AND BIOMARKERS
-Correlation of Apoptosis, p53, and Mitochondria

TARGETING THE TUMOR MICROENVIRONMENT
-Vaccines
-Legumain-based vaccines
-Prodrugs
-Peritumoral Acinar Tissue Imaging

IMAGING OF TUMORS
-Proteomic Mapping and Imaging
-Imaging of Signal Transduction Pathways
-Imaging of Tumors/Microenvironment
-Monitoring of Cyclooxygenase-2 (Cox-2) to Assess Tumor Progression VECTORS
-Pancreatic Cancer-specific Vector
-Breast Cancer-specific Vector
-Endostatin Prodrug
-Viral-based Therapy for Multiple Myeloma
-Targeted adn Shielded Adenovirus Vectors
-Whole Cell Vaccines for Acute Myeloid Leukemia (AML)
-Replication-competent Retroviral (RCR) Vectors

LIST OF EXHIBITS

Exhibit 1 - Potential Treatment Implication(s) of Selected Related EGFr Pathway Mutations
Exhibit 2 - EGFr Family Member Expression Rates (%) in Human Malignancies
Exhibit 3 - Epidermal Growth Factor (EGF) Receptor (EGFr) in Malignancy
Exhibit 4 - HEr2/neu (Her-2/neu) in Malignancy
Exhibit 5 - ErbB3 in Malignancy
Exhibit 6 - ErbB4 in Malignancy
Exhibit 7 - Epidermal Growth Factor Receptor Variant III (EGFrvIII) in Malignancy
Exhibit 8 - Selected EGFr Family Small Molecule Tyrosine Kinase Inhibitors (TKI)
Exhibit 9 - Selected ErbB Receptor-Based Immunotherapies/Vaccine Approaches
Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown
Adroll
adroll